Additionally, once T-cell redirecting therapies become widely available, the ideal sequencing of anti-CD3xCD20 BsAbs with anti-CD19 CAR T-cell therapy will need to be determined, with unique answers likely existing for different lymphoma subtypes. This evidence concerns the gene CD19 and lymphoma.